Statement: Patient who have recently undergone External beam radiation therapy are eligible for the primary trial.
Primary_evidence: Inclusion Criteria:   Histologically or cytologically confirmed invasive breast cancer, with stage IV disease   Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as greater than or equal to 20mm with conventional techniques or as greater than or equal to 10mm with spiral CT scan.   Primary tumor or metastasis must overexpress HER2   Patient must have received 1-2 prior chemotherapeutic regiments for metastatic breast cancer and must have been off treatment for at least three weeks.   Patient must have received and progressed on at least 1 prior trastuzumab-containing regimen, but not more than 2, in the metastatic setting.   Patients may have received prior radiation therapy   Patients may have received hormonal therapy in the adjuvant or metastatic setting   18 years of age or older   Life expectancy of greater than 6 months   Normal organ and marrow function as defined in the protocol   Left ventricular ejection fraction (LVEF) greater than or equal to the institutional lower limit of normal Exclusion Criteria:   Treatment with any investigational drug within 4 weeks   Long-term treatment, over 3 months, with a systemic steroid or another immunosuppressive agent   Other malignancies within the past 3 years, except for adequately treated carcinoma of teh cervix or basal-or squamous-cell carcinoma of the skin   Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001   An active, bleeding diathesis or an oral anti-vitamin K medication   Prior treatment with an mTOR inhibitor   History of non-compliance with medical regimens   Unwillingness or inability to comply with the protocol   Major surgery within 2 weeks before study entry   Patients with active brain metastases or leptomeningeal carcinomatosis   Patients who have experienced grade 1 or grade 2 hypersensitivity reactions to prior trastuzumab therapy are eligible ONLY IF these reactions did not prevent further administration   Severe and/or uncontrolled intercurrent medical condition, psychiatric illness or a social situation that could limit their ability to comply with the study requirements.   Pregnant or breast-feeding women   HIV positive patients   Known hypersensitivity to RAD001 (everolimus) or other rapamycins